These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 15284852

  • 21. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
    Kim DH, Popradi G, Sriharsha L, Kamel-Reid S, Chang H, Messner HA, Lipton JH.
    Cancer; 2008 Aug 15; 113(4):772-81. PubMed ID: 18543309
    [Abstract] [Full Text] [Related]

  • 22. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
    Pienkowska-Grela B, Woroniecka R, Solarska I, Kos K, Pastwińska A, Konopka L, Majewski M.
    Cancer Genet Cytogenet; 2007 Apr 15; 174(2):111-5. PubMed ID: 17452251
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
    Sureda A, Carrasco M, de Miguel M, Martínez JA, Conde E, Sanz MA, Díaz-Mediavilla J, Sierra J.
    Haematologica; 2003 Nov 15; 88(11):1213-20. PubMed ID: 14607749
    [Abstract] [Full Text] [Related]

  • 25. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy.
    Lange T, Bumm T, Otto S, Al-Ali HK, Kovacs I, Krug D, Köhler T, Krahl R, Niederwieser D, Deininger MW.
    Haematologica; 2004 Jan 15; 89(1):49-57. PubMed ID: 14754606
    [Abstract] [Full Text] [Related]

  • 26. Y253H mutation appearing in a micro-BCR-ABL (e19a2) CML.
    Popovici C, Charbonnier A, Gisserot O, Aguilon P, Rémy V, Olschwang S, Mozziconacci MJ.
    Leuk Res; 2008 Feb 15; 32(2):361-2. PubMed ID: 17412419
    [No Abstract] [Full Text] [Related]

  • 27. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
    Bianchini M, De Brasi C, Gargallo P, Gonzalez M, Bengió R, Larripa I.
    Eur J Haematol; 2009 Apr 15; 82(4):292-300. PubMed ID: 19191867
    [Abstract] [Full Text] [Related]

  • 28. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.
    Press RD, Galderisi C, Yang R, Rempfer C, Willis SG, Mauro MJ, Druker BJ, Deininger MW.
    Clin Cancer Res; 2007 Oct 15; 13(20):6136-43. PubMed ID: 17947479
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib.
    Moravcová J, Rulcová J, Polák J, Zemanová Z, Klamová H, Haskovec C.
    Leuk Res; 2005 Nov 15; 29(11):1365-6. PubMed ID: 15876454
    [No Abstract] [Full Text] [Related]

  • 31. Cytogenetic and molecular mechanisms of resistance to imatinib.
    Hochhaus A.
    Semin Hematol; 2003 Apr 15; 40(2 Suppl 2):69-79. PubMed ID: 12783379
    [Abstract] [Full Text] [Related]

  • 32. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y, Hardling M, Olsson B, Hezaveh R, Ricksten A, Stockelberg D, Wadenvik H.
    Ann Hematol; 2006 Dec 15; 85(12):841-7. PubMed ID: 17006667
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript.
    Li X, Yang J, Chen X, Liu J, Li H, Zheng J, He Y, Chen Z, Huang S.
    Cancer Genet Cytogenet; 2007 Jul 15; 176(2):166-8. PubMed ID: 17656262
    [Abstract] [Full Text] [Related]

  • 35. Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia.
    de Lemos JA, de Oliveira CM, Scerni AC, Bentes AQ, Beltrão AC, Bentes IR, Azevedo TC, Maradei-Pereira LM.
    Genet Mol Res; 2005 Dec 30; 4(4):803-11. PubMed ID: 16475128
    [Abstract] [Full Text] [Related]

  • 36. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
    Kim YJ, Kim DW, Lee S, Min CK, Goh HG, Kim SH, Lee JY, Kim YL, Kim HJ, Kim HJ, Lee JW, Kim TG, Min WS, Kim CC.
    Biol Blood Marrow Transplant; 2004 Oct 30; 10(10):718-25. PubMed ID: 15389438
    [Abstract] [Full Text] [Related]

  • 37. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration.
    Campbell LJ, Patsouris C, Rayeroux KC, Somana K, Januszewicz EH, Szer J.
    Cancer Genet Cytogenet; 2002 Nov 30; 139(1):30-3. PubMed ID: 12547154
    [Abstract] [Full Text] [Related]

  • 38. [Dual-color/dual-fusion interphase fluorescence in situ hybridization probe for monitoring tumor load during imatinib therapy for chronic myeloid leukemia].
    DU QF, Zhang S, Liu XL, Meng FY.
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jan 30; 30(1):123-5. PubMed ID: 20118001
    [Abstract] [Full Text] [Related]

  • 39. Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate.
    Aleem A, Siddiqui N.
    Leuk Lymphoma; 2005 Jul 30; 46(7):1097-9. PubMed ID: 16019565
    [Abstract] [Full Text] [Related]

  • 40. Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation.
    Oshikawa G, Kurosu T, Arai A, Murakami N, Miura O.
    Cancer Genet Cytogenet; 2010 May 30; 199(1):56-61. PubMed ID: 20417871
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.